Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.

about

Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.

Item

http://www.wikidata.org/entity/Q47756560

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Etoricoxib improves osteoarthr ...... f life in the extreme elderly.

@en

Etoricoxib improves osteoarthr ...... f life in the extreme elderly.

@nl

type

Item

label

Etoricoxib improves osteoarthr ...... f life in the extreme elderly.

@en

Etoricoxib improves osteoarthr ...... f life in the extreme elderly.

@nl

prefLabel

Etoricoxib improves osteoarthr ...... f life in the extreme elderly.

@en

Etoricoxib improves osteoarthr ...... f life in the extreme elderly.

@nl

P1476

Etoricoxib improves osteoarthr ...... f life in the extreme elderly.

@en

P2093

Tim K Tso

http://www.w3.org/2001/XMLSchema#string

Wen-Nan Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Acetaminophen for osteoarthritis

The search for novel analgesics: targets and mechanisms

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

Celecoxib for the prevention of sporadic colorectal adenomas

Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

Osteoarthritis: new insights. Part 2: treatment approaches.

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

P304

87-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.17305/BJBMS.2017.2214

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28954205

http://www.w3.org/2001/XMLSchema#string

P921

quality of life

osteoarthritis

P932

5826680

http://www.w3.org/2001/XMLSchema#string